Business Context and Reporting Period
Company: McKesson Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: November 23, 2010
Event: Entry into a Material Definitive Agreement to secure financing for the proposed acquisition of US Oncology Holdings, Inc.
Key Financial Metrics and Obligations
- Bridge Loan Amount: Up to $2.0 billion in aggregate principal.
- Loan Structure: One-year unsecured Senior Bridge Term Loan.
- Administrative Agent: Bank of America, N.A.
- Interest Rate Basis: Prime rate or London Interbank Offering Rate (LIBOR).
- Debt Covenant: Total debt to total capitalization ratio must not exceed 56.5%.
- Use of Proceeds: Pay merger consideration, repay US Oncology indebtedness, and cover transaction costs.
Material Changes and Strategic Actions
The filing announces the execution of a $2.0 billion bridge loan agreement on November 23, 2010. This action represents a material change in the company's capital structure intended to fund the acquisition of US Oncology prior to the closing of anticipated permanent financing. The agreement includes standard limitations on creating liens, engaging in certain mergers, and entering into swap contracts.
Outlook, Management Commentary, and Risks
- Refinancing Plan: Management expects to refinance all or part of the outstanding bridge loan amounts with longer-term debt financing before the one-year term expires.
- Mandatory Prepayments: The agreement requires prepayment of loans using net cash proceeds from equity issuances, property loss events, asset sales, or the incurrence of certain indebtedness outside the ordinary course of business.
- Related Party Transactions: Certain lenders and their affiliates have provided and may continue to provide banking and advisory services to the Company for customary fees.
Investor Verification Checklist
- Verify the closing status of the US Oncology acquisition and the final purchase price.
- Monitor the company's ability to secure permanent long-term financing to replace the bridge loan within one year.
- Review the company's total debt to total capitalization ratio to ensure compliance with the 56.5% covenant.
- Assess the impact of mandatory prepayment provisions on future liquidity if asset sales or equity issuances occur.